Pilot Project #2
Pilot Project #2
批准号:
8849781
负责人:
Selvarangan Ponnazhagan
金额:
$4.48万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-23 至 2018-08-31
关键词:
AddressAdenocarcinomaAdoptive ImmunotherapyAlabamaAnimal ModelAutoimmunityCD4 Positive T LymphocytesCD8B1 geneCancer VaccinesCell LineCell ProliferationCellsCessation of lifeCollaborationsCommunitiesComprehensive Cancer CenterDevelopmentFrequenciesFutureGoalsGrowth FactorHumanImmune responseImmunosuppressive AgentsMalignant NeoplasmsMalignant neoplasm of prostateManuscriptsMeasuresMediatingMentorsMentorshipMinority-Serving InstitutionMouse Cell LineMusNatural Killer CellsOrganOutcomePC3 cell linePilot ProjectsProductionProstateProstatic NeoplasmsRegulatory T-LymphocyteResearchResearch PersonnelResearch TrainingRoleSecond Primary CancersT-LymphocyteTraining and EducationTransforming Growth Factor betaTransforming Growth FactorsTransgenic MiceTransgenic OrganismsTumorigenicityUnited StatesUniversitiesUniversity of Alabama at Birmingham Cancer CenterVisionWorkanticancer researchbaseblocking factorcancer diagnosiscancer health disparitycancer initiationcareercareer developmentdesignexperienceimmune functionmenneoplastic cellprostate cancer cellracial and ethnicresponsetranscription factortranslational studytumortumor microenvironmenttumor progression
中文摘要
项目摘要:前列腺癌(Pca)是最常见的非皮肤恶性肿瘤,其次是癌症
对美国男性的死亡负有责任。先前对前列腺癌动物模型和人类的研究
证明了前列腺会产生各种生长因子。这些因子的加入或阻断改变了PCA细胞
具有增殖等功能。在这些因子中,转化生长因子-β-1(转化生长因子-β)参与了
致瘤性,显示出强大的免疫抑制活性,是转换传统的CD4+所必需的
T细胞转化为FoxP3+调节性T(Tr)细胞。表达转录因子Foxp3的TR细胞对正常
免疫功能;缺乏tr细胞会导致多器官自身免疫和死亡。明确转化生长因子-β的作用及其机制
在前列腺癌的发生和发展过程中对TR值的影响缺乏实验证据。
在这项提案中,我们计划研究转化生长因子-β和/或tr的潜在机制。
来自前列腺癌转基因小鼠(TRAMP)的Pca细胞系,在C57/B6小鼠中。在这些细胞系中,
TRAMP-C1和TRAMP-C2形成肿瘤;TRAMP-C3不能形成肿瘤。这些前列腺癌小鼠细胞系可用于
获得这个项目的长期目标,即解决根本问题:是否要做tr细胞和/或转化生长因子-β
水平与TRAMP细胞系(C1、C2和C3)致瘤性的差异有关?这个项目的目标是
确定宿主细胞产生转化生长因子-β对TRAMP细胞系的反应或转化生长因子-β表达的作用
探讨转化生长因子-β在初始CD_4~+T细胞向表达Foxp3的T细胞转化中的作用。
英文摘要
Project Summary: Prostate cancer (PCa) is the most common non-skin malignancy and the cancer second most
responsible for death in men in United States. Prior studies with animal models of PCa and with humans
demonstrated that the prostate produces various growth factors. Addition or blocking of these factors alters PCa cell
proliferation and other functions. Among these factors, transforming growth factor-β1 (TGF-β) is involved in
tumorigenicity, displays potent immunosuppressive activities, and is required for the conversion of conventional CD4+
T cells to FoxP3+ regulatory T (TR) cells. TR cells that express the transcription factor Foxp3 are essential for normal
immune function; absence of TR cells results in multi-organ autoimmunity and death. A clear role of TGF-β and its
effect on TR during PCa development and progression lacks experimental evidence.
In this proposal, we plan to investigate the underlying mechanisms involved in the context of TGF-β and/or TR using
PCa cell lines, derived from transgenic mouse for prostate cancer (TRAMP), in C57/B6 mice. Of these cell lines,
TRAMP- C1 and TRAMP-C2 form tumors; TRAMP-C3 fails to do so. These mouse cell lines of PCa can be used to
obtain the long-term goal of this project, which is to address the fundamental question: Do TR cells and/or TGF-β
levels relate to differences in tumorigenicity of the TRAMP cell lines (C1, C2, and C3)? The objective of this project is
to define the role of TGF-β production by host cells in response to or TGF-β expression by TRAMP cell lines and to
establish the function of TGF-β on the conversion of naive CD4+ T cells into Foxp3-expressing TR cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms and therapeutic targeting of osteoimmune functions of RANKL in breast cancer
-
批准号:10586000
-
项目类别:
-
资助金额:$44.67万
-
财政年份:2023
-
负责人:Selvarangan Ponnazhagan
-
依托单位:
Targeted therapy for breast cancer with osteolytic bone damage
-
批准号:9207743
-
项目类别:
-
资助金额:$33.63万
-
财政年份:2015
-
负责人:Selvarangan Ponnazhagan
-
依托单位:
Targeted therapy for breast cancer with osteolytic bone damage
-
批准号:8824806
-
项目类别:
-
资助金额:$32.12万
-
财政年份:2015
-
负责人:Selvarangan Ponnazhagan
-
依托单位:
Targeted Stem Cell Therapy Coupling Angiogenesis and Osteogenesis for Bone Defect
-
批准号:8293090
-
项目类别:
-
资助金额:$32.96万
-
财政年份:2011
-
负责人:Selvarangan Ponnazhagan
-
依托单位:
Targeted Stem Cell Therapy Coupling Angiogenesis and Osteogenesis for Bone Defect
-
批准号:8538294
-
项目类别:
-
资助金额:$31.31万
-
财政年份:2011
-
负责人:Selvarangan Ponnazhagan
-
依托单位:
Targeted Stem Cell Therapy Coupling Angiogenesis and Osteogenesis for Bone Defect
-
批准号:8087215
-
项目类别:
-
资助金额:$32.96万
-
财政年份:2011
-
负责人:Selvarangan Ponnazhagan
-
依托单位:
Gene-Engineered and Targeted Stem Cell Therapy for Myeloma
-
批准号:8052705
-
项目类别:
-
资助金额:$29.18万
-
财政年份:2009
-
负责人:Selvarangan Ponnazhagan
-
依托单位:
Gene-Engineered and Targeted Stem Cell Therapy for Myeloma
-
批准号:8247151
-
项目类别:
-
资助金额:$29.18万
-
财政年份:2009
-
负责人:Selvarangan Ponnazhagan
-
依托单位:
Gene-Engineered and Targeted Stem Cell Therapy for Myeloma
-
批准号:7797470
-
项目类别:
-
资助金额:$30.09万
-
财政年份:2009
-
负责人:Selvarangan Ponnazhagan
-
依托单位:
Gene-Engineered and Targeted Stem Cell Therapy for Myeloma
-
批准号:7590067
-
项目类别:
-
资助金额:$29.15万
-
财政年份:2009
-
负责人:Selvarangan Ponnazhagan
-
依托单位:
Gene-Engineered and Targeted Stem Cell Therapy for Myeloma
-
批准号:8450738
-
项目类别:
-
资助金额:$27.43万
-
财政年份:2009
-
负责人:Selvarangan Ponnazhagan
-
依托单位:
rAAV vaccine vector
-
批准号:8306344
-
项目类别:
-
资助金额:$29.18万
-
财政年份:2008
-
负责人:Selvarangan Ponnazhagan
-
依托单位:
rAAV vaccine vector
-
批准号:7671315
-
项目类别:
-
资助金额:$30.09万
-
财政年份:2008
-
负责人:Selvarangan Ponnazhagan
-
依托单位:
rAAV vaccine vector
-
批准号:7899763
-
项目类别:
-
资助金额:$30.09万
-
财政年份:2008
-
负责人:Selvarangan Ponnazhagan
-
依托单位:
rAAV vaccine vector
-
批准号:8101137
-
项目类别:
-
资助金额:$29.18万
-
财政年份:2008
-
负责人:Selvarangan Ponnazhagan
-
依托单位:
AAV-mediated gene therapy for metabolic bone disease
-
批准号:7483090
-
项目类别:
-
资助金额:$26.77万
-
财政年份:2005
-
负责人:Selvarangan Ponnazhagan
-
依托单位:
AAV-Mediated Gene Therapy for Metabolic Bone Disease
-
批准号:7676053
-
项目类别:
-
资助金额:$26.77万
-
财政年份:2005
-
负责人:Selvarangan Ponnazhagan
-
依托单位:
AAV-mediated gene therapy for metabolic bone disease
-
批准号:6867952
-
项目类别:
-
资助金额:$28.79万
-
财政年份:2005
-
负责人:Selvarangan Ponnazhagan
-
依托单位:
AAV-mediated gene therapy for metabolic bone disease
-
批准号:7280959
-
项目类别:
-
资助金额:$27.32万
-
财政年份:2005
-
负责人:Selvarangan Ponnazhagan
-
依托单位:
AAV-mediated gene therapy for metabolic bone disease
-
批准号:7108511
-
项目类别:
-
资助金额:$28.13万
-
财政年份:2005
-
负责人:Selvarangan Ponnazhagan
-
依托单位:
国内基金
海外基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
-
批准号:30840003
-
项目类别:专项基金项目
-
资助金额:12.0万元
-
批准年份:2008
-
负责人:焦宇飞
-
依托单位: